OptiBiotix Health PLC Notice of Results (4299B)
April 04 2017 - 1:01AM
UK Regulatory
TIDMOPTI
RNS Number : 4299B
OptiBiotix Health PLC
04 April 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Notice of Results
Analyst and Investor Briefing
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, will announce its final results for the year ended
30 November 2016 on Tuesday, 25 April 2017.
Analyst briefing
A briefing for analysts only will take place at the offices of
Walbrook PR, 4 Lombard St., London EC3V 9HD at 9.30am on Tuesday 25
April 2017.
Investor presentation
Stephen O'Hara will be giving a presentation for investors on
the afternoon of Tuesday 25 April 2017 in the Grill room at the
London Capital Club, 15 Abchurch Lane, London EC4N 7BW from 4.30pm
for a 4.45pm start. The presentation will outline the Company's
strategy to deliver value for shareholders and give an update for
the year. This will be followed by light refreshments and an
opportunity to network.
If you would like to register to attend either briefing, or
require further information, please contact Walbrook PR on 020 7933
8780 or email optibiotix@walbrookpr.com.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213
0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORLLFFESSIVIID
(END) Dow Jones Newswires
April 04, 2017 02:01 ET (06:01 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024